-- CARsgen Therapeutics (HKG:2171) booked 97.9 million yuan in attributable loss for 2025, narrowing from a loss of 798.1 million yuan in 2024, according to a Hong Kong bourse filing Friday.
Shares of the cell therapy developer gained over 2% in morning trade Monday.
Loss per share was 0.18 yuan, compared with 1.44 yuan in the prior year.
Revenue rose to 125.7 million yuan from 39.4 million yuan in 2024, figures showed.